US Patent

US11096913 — High-stability packaged solutions of T4 thyroid hormone

Formulation · Assigned to Altergon SA · Expires 2037-02-28 · 11y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects highly stable, alcohol-free solutions of T4 thyroid hormone packaged in multi-barrier containers with reduced T3 impurity.

USPTO Abstract

The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.

Drugs covered by this patent

Patent Metadata

Patent number
US11096913
Jurisdiction
US
Classification
Formulation
Expires
2037-02-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Altergon SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.